This feature article highlights the most recent advances in nanoparticle-enabled delivery of proteolysis-targeting chimeras (PROTACs) for spatiotemporally controlled protein degradation.
A review on current proteolysis targeting chimeras (PROTACs) as chemical probes for histone deacetylase (HDAC) enzymes.
PROTAC–Pt(IV) represents a new class of dual-action Pt(IV) prodrugs integrating platinum drugs with PROTAC-mediated protein degradation, exhibiting superior antitumor efficacy compared to conventional Pt(IV) prodrug and PROTAC alone in vivo.
Machine learning (ML) accelerates PROTAC design by optimizing linkers and protein–ligase interactions, enabling selective protein degradation for therapeutic applications, particularly targeting previously undruggable proteins.
Schematic illustration of the combinational strategy of nanotechnology and PROTACs (Nano-PROTACs): the typical shortcomings of traditional PROTACs and the nanotechnology-based strategies for PROTAC drugs optimization.